The uncertainty about U.S. pharmaceutical tariffs shouldn't be as worrisome for AstraZeneca now.

Shares of AstraZeneca ( AZN -0.82% ) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early breast cancer. However, the main reason for AstraZeneca's big gain was Pfizer 's ( PFE -0.99% ) announcement of a deal with the Trump administration.

Pfizer CEO Albert Bourla appeared with President Donald Trump at a press conference on Tuesday to announce the landmark agreement. Pfizer plans to slash the prices on many of its prescription drugs in the U.S. and invest $70 billion in expanding its domestic operations. It will also participate in a new TrumpRx website that will help c

See Full Page